Research Article

Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome

Volume: 20 Number: 3 October 1, 2023
TR EN

Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome

Abstract

Aim: The myeloperoxidase/paraoxonase1(MPO/PON1) ratio is known to reflect the dysfunctional HDL(d-HDL) which is a measure of oxidative stress. This study aimed to evaluate the MPO/PON1 ratio in polycystic ovary syndrome(PCOS). Materials and Method: This prospective study included a total of 123 patients. The study group including the women with the diagnosis of PCOS (n=63) was compared to the control group including the healthy women (n=60). Sociodemographic characteristics, and clinical features of the groups were recorded. Serum HDL level, MPO, and PON1 activities were evaluated. Results: The PCOS patients were observed to have increased MPO and decreased PON1 activities (p<0.0001 and p=0.007, respectively). The d-HDL and was found to be significantly higher in PCOS patients compared to the healthy controls (0.56 (0.24) vs. 0.50 (0.12), p<0.0001). There were also significant associations between the oxidative parameters and PCOS related findings (p<0.05). Conclusion: Besides the increased MPO/PON1 ratio which defined as d-HDL, the increased MPO and decreased PON1 activities also supported the increased oxidative status in PCOS patients. Our results may be considered to draw attention to oxidative stress and dyslipidemia in PCOS patients, even in the early periods of the women life.

Keywords

References

  1. 1. Escobar-Morreale HF. Polycystic ovary syndrome: de- finition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84. 2. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analy- sis. Hum Reprod Update. 2011;17(4):495-500. 3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993-1007. 4. Perovic Blagojevic IM, Vekic JZ, Macut DP, Ignjato- vic SD, Miljkovic-Trailovic MM, Zeljkovic AR, et al. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2022;128(4):604-12. 5. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fo- narow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46(10):1792-8.

Details

Primary Language

English

Subjects

Obstetrics and Gynaecology

Journal Section

Research Article

Publication Date

October 1, 2023

Submission Date

June 12, 2023

Acceptance Date

July 6, 2023

Published in Issue

Year 2023 Volume: 20 Number: 3

APA
Erol Koç, E. M., Yaman, S., Ceyhan, M., Neselioglu, S., Erel, Ö., & Doğanay, M. (2023). Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. Jinekoloji-Obstetrik Ve Neonatoloji Tıp Dergisi, 20(3), 1804-1809. https://doi.org/10.38136/jgon.1313215
AMA
1.Erol Koç EM, Yaman S, Ceyhan M, Neselioglu S, Erel Ö, Doğanay M. Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi. 2023;20(3):1804-1809. doi:10.38136/jgon.1313215
Chicago
Erol Koç, Esin Merve, Selen Yaman, Meryem Ceyhan, Salim Neselioglu, Özcan Erel, and Melike Doğanay. 2023. “Evaluation of the Myeloperoxidase Paraoxonase1 Ratio As the Determinant of Dysfunctional HDL in Polycystic Ovary Syndrome”. Jinekoloji-Obstetrik Ve Neonatoloji Tıp Dergisi 20 (3): 1804-9. https://doi.org/10.38136/jgon.1313215.
EndNote
Erol Koç EM, Yaman S, Ceyhan M, Neselioglu S, Erel Ö, Doğanay M (October 1, 2023) Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi 20 3 1804–1809.
IEEE
[1]E. M. Erol Koç, S. Yaman, M. Ceyhan, S. Neselioglu, Ö. Erel, and M. Doğanay, “Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome”, Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, vol. 20, no. 3, pp. 1804–1809, Oct. 2023, doi: 10.38136/jgon.1313215.
ISNAD
Erol Koç, Esin Merve - Yaman, Selen - Ceyhan, Meryem - Neselioglu, Salim - Erel, Özcan - Doğanay, Melike. “Evaluation of the Myeloperoxidase Paraoxonase1 Ratio As the Determinant of Dysfunctional HDL in Polycystic Ovary Syndrome”. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi 20/3 (October 1, 2023): 1804-1809. https://doi.org/10.38136/jgon.1313215.
JAMA
1.Erol Koç EM, Yaman S, Ceyhan M, Neselioglu S, Erel Ö, Doğanay M. Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi. 2023;20:1804–1809.
MLA
Erol Koç, Esin Merve, et al. “Evaluation of the Myeloperoxidase Paraoxonase1 Ratio As the Determinant of Dysfunctional HDL in Polycystic Ovary Syndrome”. Jinekoloji-Obstetrik Ve Neonatoloji Tıp Dergisi, vol. 20, no. 3, Oct. 2023, pp. 1804-9, doi:10.38136/jgon.1313215.
Vancouver
1.Esin Merve Erol Koç, Selen Yaman, Meryem Ceyhan, Salim Neselioglu, Özcan Erel, Melike Doğanay. Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi. 2023 Oct. 1;20(3):1804-9. doi:10.38136/jgon.1313215